X-HA^{3®} The 1st polyvalent cross-linked Hyaluronic acid dermal filler

3 INDICATIONS

For all cutaneous depressions linked to age Medium wrinkles - Deep wrinkles - Lips: contours and volume

- Nasolabial folds
- Marionette lines
- Facial contours
- Peribuccal wrinkles
- Tear trough
- Glabella
- Labial commissures
- Lip volume
- Cheekbones

EXCLUSIVE FORMULATION

Adapted to different depths

- Monophasic and resorbable implant (without particles)
- Optimal concentration: 23mg/ml cross-linked hyaluronic acid
- High molecular weight: 2,5 millions daltons

INJECTION

X-HA^{3®} can be injected in middle and deep dermis

ADVANTAGES

/ OPTIMAL VISCOSITY

Only a small quantity of X-HA3[®] is sufficient to create a volume able to lift tissues in order to correct medium and deep wrinkles. This volume property is given by the unique visco-elasticity obtained thanks to an important molecular weight combined to a high concentration of hyaluronic acid and an adapted cross-linking.


/ MODELLING

Once injected, X-HA3[®] gel can be sculpted, modeled and easily positioned in tissues, so that it re-creates harmonious contours of the face. This high modelling capacity allows the treatment of the medium depressions with natural effects.

/ HOMOGENEOUS

Thanks to an exceptional homogeneity, X-HA3[®] gel has an equal consistency and a uniform density, allowing a precise and regular injection, for natural results.

/ INJECTION STRENGTH



Gel A : monophasic with 25 mg/g , filler of cross-linked hyaluronic acid Gel B : monophasic with 22,5 mg/g, filler of cross-linked hyaluronic acid Gel C : monophasic with 24 mg/g, filler of cross-linked hyaluronic acid

X-HA^{3®} PROVEN EFFICACY AND SAVETY

TOLERANCE

/ Very good tolerance in the weeks following the injection

/ Good integration in the tissues


			Ecchymosis
Light	2 After 1 st injection	0	0
Moderate	0	0	0
Severe	0	0	0

*Results of a multicentric study carried out on 95 patients -Évaluation des effets secondaires, immédiatement, après 1 semaine, 3 mois, 6 mois

EFFICACY AND REMANENCE


Measured through several clinical studies

/ Follow-up during 8 months - Multicentric study carried out on 95 patients (1)



/ Follow-up during 6 months - Monocentric study carried out on 30 patients
Remanance of aesthetic results during 6 months minimum

Evaluation clinique du degrès de la ride au moyen de l'échelle WSRS (Wrinkle severity rating scale)



• Remanance of the OCR (Optimal Cosmetic Result) during 6 months

Maintaining long-lasting ORC				
to 1 month 100%	to 3 months 96%	to 6 months 73%		
Å		÷		

Conclusion: significant improvement and lasting results of the injection.

PHYSICIAN AND PATIENTS SATISFACTION

Evaluating physician satisfaction and patients / The physician is satisfied for 100% of his treatments.

100% OF PATIENTS ARE SATISFIED (EVEN 70% VERY SATISFIED

96% OF IMPROVEMENTALL VISIBLE AT 6 MONTHS

Monocentric study on 95 patients - follow-up during 8 months - Evolution scoring of wrinkles, tolerance evaluation.
Monocentric study on 30 patients - follow-up during - Evaluation on standardized pictures.